Residency · Residency · Medical Genetics Genomics
Dilated Cardiomyopathy: Genetic Contributions and Family Screening
Introduction
Dilated cardiomyopathy (DCM) is characterized by left ventricular dilation and systolic dysfunction in the absence of abnormal loading conditions or coronary artery disease sufficient to explain the degree of impairment. Approximately 30-50% of DCM cases are familial, underscoring the critical role of genetic evaluation and cascade screening in clinical management.
Epidemiology and Clinical Presentation
DCM prevalence is estimated at 1 in 250-500 individuals, and it is the leading indication for cardiac transplantation worldwide. Presentation ranges from asymptomatic ventricular dilation to advanced heart failure. Age of onset is highly variable, spanning from infancy to late adulthood, and males are affected more frequently than females at a ratio of approximately 3:1.
Genetic Architecture of DCM
Major Gene Categories
Sarcomeric genes represent the largest category, with TTN (titin) truncating variants accounting for 15-25% of familial DCM, making it the single most common genetic cause. Cytoskeletal genes include DES (desmin), DMD (dystrophin), and FLNC (filamin C). Nuclear envelope genes, particularly LMNA (lamin A/C), are associated with DCM plus conduction disease and high risk of sudden cardiac death. Desmosomal genes such as DSP (desmoplakin) show overlap with arrhythmogenic cardiomyopathy. Ion channel and calcium handling genes include SCN5A and PLN (phospholamban).
Inheritance Patterns
Autosomal dominant is the most common pattern, accounting for approximately 90% of familial cases. X-linked inheritance occurs in dystrophin-related DCM (carriers of Duchenne/Becker muscular dystrophy). Autosomal recessive inheritance is rare and seen in metabolic cardiomyopathies. De novo variants are increasingly recognized, particularly in pediatric-onset cases.
Genotype-Phenotype Correlations
High-Risk Genotypes
LMNA variants are associated with progressive conduction disease, atrial fibrillation, ventricular arrhythmias, and sudden cardiac death, with lower ICD implantation thresholds per guidelines. FLNC truncating variants carry a high burden of ventricular arrhythmias and myocardial fibrosis visible on cardiac MRI. DSP truncating variants produce episodic myocardial injury (troponin elevation), left ventricular fibrosis, and arrhythmic risk. RBM20 variants cause early-onset aggressive DCM with significant arrhythmic burden.
TTN Truncating Variants
TTN truncating variants are most commonly pathogenic when located in the A-band region of titin. Incomplete penetrance complicates family counseling. The population frequency of TTN truncating variants is approximately 1-3%, requiring careful clinical-genetic correlation to avoid misattribution.
| Gene | Frequency in Familial DCM | Key Phenotype Features | Arrhythmia Risk | Special Considerations |
|---|---|---|---|---|
| TTN (truncating) | 15–25% | Pure DCM; may be peripartum | Moderate (AF common) | A-band location most significant; population TTNtv ~1–3% |
| LMNA | 5–10% | DCM + conduction disease + AF | Very high (VT/VF; SCD) | Lower LVEF threshold for ICD |
| FLNC (truncating) | 3–5% | DCM with ring-like fibrosis on CMR | High (VT) | Fibrosis is hallmark |
| DSP (truncating) | 2–5% | Episodic troponin; LV fibrosis | High | Overlap with arrhythmogenic cardiomyopathy |
| RBM20 | 2–3% | Early-onset aggressive DCM | High | Often young patients |
| MYH7 | 3–5% | DCM (also HCM gene) | Variable | Overlaps with HCM |
| SCN5A | 2–3% | DCM + arrhythmia + Brugada overlap | High | Sodium channel dysfunction |
Diagnostic Approach
Clinical Evaluation
A detailed three-generation pedigree should document heart failure, sudden death, pacemaker or ICD implantation, and neuromuscular disease. Echocardiography demonstrates a left ventricular end-diastolic diameter more than 2 standard deviations above normal with ejection fraction below 45%. Cardiac MRI is the gold standard for fibrosis detection via late gadolinium enhancement. ECG findings may include low voltage, conduction disease, and arrhythmias.
Genetic Testing Strategy
Gene panel testing (typically 30-100 genes) is first-line for suspected genetic DCM. Broader panels or exome sequencing are considered when the initial panel is negative and clinical suspicion remains high. Variant interpretation follows ACMG/AMP guidelines with ClinGen-curated gene-disease validity assessments. The ClinGen DCM Gene Curation Expert Panel has classified genes by strength of evidence (definitive, strong, moderate, limited).
Family Screening Protocol
First-degree relatives should undergo clinical screening starting at diagnosis of the proband. Screening includes ECG, echocardiography, and consideration of cardiac MRI. When a pathogenic variant is identified, predictive genetic testing guides which relatives require ongoing surveillance. Variant-negative relatives can be released from surveillance. Variant-positive or genetically untested relatives require serial screening every 1-3 years through adulthood. Pediatric screening should begin by age 10-12 years or earlier if the family variant is associated with childhood onset.
Management Considerations Informed by Genotype
LMNA DCM warrants a lower threshold for ICD implantation based on risk calculators such as the Lamin A/C Risk-VTA Calculator, along with early referral for advanced heart failure therapies. TTN DCM generally carries a more favorable prognosis with guideline-directed medical therapy and a higher likelihood of reverse remodeling. All genetic DCM patients benefit from neurohormonal blockade (ACE inhibitors/ARBs/ARNI, beta-blockers, MRA, SGLT2 inhibitors). Exercise restriction counseling varies by genotype, with more restrictive recommendations for LMNA, FLNC, and DSP variants.
Clinical Pearls
TTN truncating variants are the most common genetic cause of DCM but exhibit incomplete penetrance, requiring careful variant interpretation and family correlation. LMNA-associated DCM carries high arrhythmic risk and warrants proactive ICD evaluation even when LVEF is only mildly reduced. A negative family history does not exclude genetic etiology due to incomplete penetrance, variable expressivity, and de novo variants. Cardiac MRI with late gadolinium enhancement provides prognostic and genotype-correlative information beyond echocardiography alone.
References
- Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nature Reviews Cardiology. 2013;10(9):531-547.
- Jordan E, Peterson L, Ai T, et al. Evidence-based assessment of genes in dilated cardiomyopathy. Circulation. 2021;144(1):7-19.
- Wilde AAM, Semsarian C, Marquez MF, et al. European Heart Rhythm Association/Heart Rhythm Society/APHRS/LAHRS Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace. 2022;24(8):1307-1367.
- Akhtar MM, Lorenzini M, Cicerchia M, et al. Clinical phenotypes and prognosis of dilated cardiomyopathy caused by truncating variants in the TTN gene. Circulation: Heart Failure. 2023;16(2):e010191.